Company / Capital Expenditures
Trevi Therapeutics, Inc. Capital Expenditures History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$35.0K
FY2024
5-year range
$32.0K / $159.0K
FY2020-FY2024
Trend
-74.5%
vs FY2023
Sector context
#181 of 194
Health Care
What the data says
Among 194 Health Care companies, Trevi Therapeutics, Inc. is in the bottom 7% for capital expenditures. Declined from $159,000 to $35,000 over the past 2 years.
Based on SEC 10-K filings.
$35,000 in FY2024 with a 5-year CAGR of +31.2%.
Declined from $159,000 to $35,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +31.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 194This company $35.0K Sector average $117.5M
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +31.2%, indicating consistent growth.
- In FY2024, capital expenditures decreased 74.5% year-over-year.
- Ranks #181 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $35.0K | -74.5% |
| FY2023 | $137.0K | -13.8% |
| FY2022 | $159.0K | - |
| FY2021 | - | - |
| FY2020 | $32.0K | +255.6% |
| FY2019 | $9.0K | -94.3% |
| FY2018 | $158.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026